TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient report describes four leading theories for what causes Alzheimer’s disease: amyloid buildup, tau damage, inflammation and problems with blood vessel health. Each may explain part of the disease process, but researchers have not established one complete cause. Current treatments aimed at amyloid can modestly slow cognitive decline for some people in the early stages; they do not cure Alzheimer’s.
Researchers still have no settled explanation for what starts Alzheimer’s disease, according to a Being Patient report outlining four leading theories: amyloid buildup, tau damage, inflammation and changes in blood vessel health. The theories describe possible parts of a disease process that damages brain cells; they are not four confirmed, competing causes, and the report says each explains only part of the picture.
Alzheimer’s is a progressive disease that damages and eventually kills neurons, the cells that carry messages through the brain and nervous system. As neurons and their connections are lost, communication breaks down. The hippocampus, which helps form new memories, is often affected early; later damage can involve language, judgment, behavior and physical coordination. The report cites the Alzheimer’s Association’s 2026 Facts and Figures report, which estimates that 7.4 million Americans age 65 and older are living with Alzheimer’s dementia.
The amyloid hypothesis, the dominant explanation for more than three decades, holds that fragments of beta-amyloid accumulate outside neurons and form plaques. Researchers propose that the buildup disrupts signaling and may trigger further damage, including tau tangles. The tau theory focuses inside neurons: tau normally supports the cell’s internal structure, while abnormal tau can form tangles associated with cell damage. The report presents inflammation and blood vessel health as two other areas of research, though the supplied material does not provide their detailed mechanisms.
The amyloid theory has shaped drug development. The FDA-approved antibodies lecanemab (Leqembi) and donanemab (Kisunla) modestly slowed cognitive decline in clinical trials among people in early stages of Alzheimer’s, according to the report. They are not cures and carry risks of brain swelling and bleeding, so treatment requires regular monitoring. Aducanumab (Aduhelm), an earlier anti-amyloid drug, cleared plaques but had unconvincing evidence of clinical benefit; its maker discontinued it in 2024.
How Theories Shape Alzheimer’s Care
The competing explanations matter because they influence which biological changes researchers measure and which treatments they test. Amyloid has also become a tool in diagnosis: the report says plaques can be detected through PET scans and spinal fluid testing, and that the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s.
Evidence that amyloid-targeting drugs can modestly slow decline supports a role for amyloid in at least some stages of disease, but it does not establish that plaques are the sole cause. The reported treatment effects also have practical limits: they apply to people in early stages, do not amount to a cure, and must be weighed against risks and monitoring needs with qualified clinicians.
Alzheimer's disease amyloid test kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Plaques To Multiple Pathways
In 1906, German psychiatrist Alois Alzheimer described changes in the brain of Auguste Deter, a former patient who died at 55 after years of memory loss, confusion and paranoia. He observed clumps between brain cells and twisted fibers within them. These are now known as amyloid plaques and tau tangles, which remain defining hallmarks of Alzheimer’s disease.
The report says amyloid buildup may begin years or decades before symptoms become apparent. That long interval is one reason researchers study biological markers as well as memory and thinking changes. The source also notes that plaques can be identified by imaging and fluid tests, while a blood test was cleared in 2025 to help identify related amyloid pathology. These developments can help identify disease-related changes, but they do not resolve what initiates the process.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, researcher at Chiesi Farmaceutici, as quoted by Being Patient
What Starts The Cell Damage?
The initiating cause remains unresolved. The report describes four leading theories, but the supplied material does not establish that any one of them explains Alzheimer’s on its own or how the proposed processes interact. It also does not provide detailed evidence for the inflammation and blood vessel theories, so their relative strength cannot be assessed from the material provided.
There is disagreement about amyloid’s role. Some scientists have proposed that beta-amyloid could have protective functions, and point to trials in which blocking its production worsened cognitive or clinical performance. At the same time, newer antibodies that remove amyloid have shown modest slowing of decline in trials. The evidence described here does not settle how amyloid contributes, which patients benefit, or how the different processes relate over time.
Research Beyond Amyloid Removal
Research will continue to test how amyloid, tau, inflammation and blood vessel health relate to brain cell damage, symptoms and one another. The report does not name a specific upcoming study or regulatory decision. For now, the cited anti-amyloid treatments are FDA-approved for people in early stages of Alzheimer’s, with regular monitoring needed because of potential brain swelling and bleeding. Decisions about testing or treatment should be made with a qualified health professional.
Key Questions
Do scientists know exactly what causes Alzheimer’s?
No. The report describes four leading theories, but says each explains only part of the disease and researchers are still working out why neurons are damaged and die.
What are amyloid plaques and tau tangles?
Amyloid plaques are clumps of beta-amyloid fragments that collect between neurons. Tau tangles form from abnormal tau inside neurons. Both are hallmarks of Alzheimer’s, but their presence alone does not explain the full cause.
Do anti-amyloid drugs cure Alzheimer’s?
No. The report says lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early stages. They do not cure the disease and can cause brain swelling or bleeding that requires monitoring.
Can a blood test identify Alzheimer’s?
The report says the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s. It describes the test as an aid, not as proof of the disease’s complete cause.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
